Is intracranial volume a suitable proxy for brain reserve?

Anna Catharina van Loenhoud1*, Colin Groot1, Jacob William Vogel1,2, Wiesje Maria van der Flier1,4 and Rik Ossenkoppele1,3,5

Abstract

Background: Brain reserve is a concept introduced to explain why Alzheimer’s disease (AD) patients with a greater brain volume prior to onset of pathology generally have better clinical outcomes. In this review, we provide a historical background of the emergence of brain reserve and discuss several aspects that need further clarification, including the dynamic or static nature of the concept and its underlying mechanisms and clinical effect. We then describe how brain reserve has been operationalized over the years, and critically evaluate the use of intracranial volume (ICV) as the most widely used proxy for brain reserve. Furthermore, we perform a meta-analysis showing that ICV is associated with higher cognitive performance after adjusting for the presence and amount of pathology. Although we acknowledge its imperfections, we conclude that the use of ICV as a proxy for brain reserve is currently warranted. However, further development of more optimal measures of brain reserve as well as a more clearly defined theoretical framework is essential.

Keywords: Brain reserve, Intracranial volume, Alzheimer's disease, Dementia, MRI, Resilience

Background

The concept of “brain reserve capacity” finds its origins in the scientific literature in the first half of the twentieth century. An article in 1940 described the remarkable observation of a 27-year-old post-traumatic epilepsy patient who retained a relatively normal intellect and personality despite surgical removal of large parts of his brain. This maintenance of function after surgery was also reported in monkeys and rats and was especially apparent when performed at a relatively young age [1]. These studies demonstrate the capacity of the brain to utilize remaining (or reserve) brain tissue to take over functions from brain regions and networks affected by injury. Approximately 40 years later, Roth [49] described a similar phenomenon in the context of dementia. He noted that many neurodegenerative diseases seem to have a long-lasting preclinical phase in which brain pathology is present without the co-occurrence of clinical symptoms. In Alzheimer’s disease (AD), for example, there is now compelling evidence that amyloid-β and tau pathology accumulate decades prior to the onset of cognitive impairment [11, 27, 28]. In his “threshold model of dementia”, Roth argued that during this preclinical phase a protective mechanism of the brain must be responsible for counteracting the effects of pathology until the pathology increases to a critical threshold at which clinical manifestation cannot be prevented any more [49]. This idea was further developed by Mortimer [42] and later also by Satz [52], who added an important dimension to the model by proposing that this pathological threshold is not uniform across individuals: some people need more pathology than others for clinical symptoms to arise. A person who initially has a larger and better-connected brain (i.e., higher premorbid brain reserve) will have more functional brain tissue remaining at a given level of pathology and will thus develop clinical symptoms at a more advanced biological stage. In other words, according to these authors, it is not the amount of pathology per se but its effect on the level of brain reserve that determines whether and when clinical manifestations occur. Their models thus concern a “reserve threshold” rather than a “pathological threshold” [42, 52]. Another influential study that provided
additional evidence that pathological thresholds for clinical expression vary between individuals was a postmortem examination described by Katzman et al. [31]. These authors described a group of subjects who showed marked presence of amyloid-β plaques and neurofibrillary tangles (and therefore met the neuropathological criteria for AD) but who had expressed minimal clinical symptoms during life. Further analyses revealed that the brains of these individuals were characterized by a higher weight and a greater number of neurons. These results led the authors to hypothesize that a larger brain size may be protective against the clinical expression of pathology “through the mechanism of reserve” [31]. Years later, Stern [60] further refined the definition of brain reserve by discerning it from cognitive reserve. While often used interchangeably in the past, Stern proposed that brain reserve is a “passive” concept (see glossary) that can be defined by the plain quantity of neural resources supporting the brain to better tolerate emerging neuropathology. In contrast, cognitive reserve, a related but distinct concept that will not be further discussed in this paper, should be considered as an “active” phenomenon (see glossary), referring to the capacity of the brain to cope with damage through more efficient use of pre-existing neural pathways or via recruitment of alternative brain networks [60]. After its introduction in 1940 and continued development throughout the following decades, the concept of brain reserve has been increasingly used in the literature (Fig. 1).

Unclarified theoretical issues
Despite the significant efforts described above, there is currently no clear consensus on several aspects of the definition and theory behind brain reserve. While there is some consensus among experts in the field that brain reserve describes the phenomenon in which a larger brain size protects against the clinical consequences of pathology, many details remain to be clarified. In the sections below, we will consider issues regarding the dynamic or static nature (see glossary) of the concept and evaluate different theoretical models to explain the mechanisms and clinical effects of brain reserve.

Dynamic or static nature of brain reserve
An issue that is currently unresolved is a lack of agreement on whether brain reserve is a dynamic or a static concept. Brain size is largely determined by biological and genetic influences [5, 48]. Since intracranial volume (ICV; discussed in more detail below, also see glossary) does not increase after the age of 10 years [47] and the brain has reached maturity around 25 years of age [20, 34, 35], brain reserve was initially thought of as a fixed concept. However, recent literature also emphasizes the role of environmental factors in dynamically shaping brain reserve over the course of life (e.g., [4]). While neuroscientists are still debating whether neurogenesis actually occurs in the adult human brain [57], it is generally accepted that in specific areas (e.g., the hippocampus and subventricular zone) new neurons (and synapses) are formed throughout life [7, 16, 32, 59]. This process is regulated by several lifestyle factors, such as exercise, diet, and social interactions [33, 66]. Brain reserve could therefore potentially increase over time and may thus be more dynamic than originally assumed.
A related theoretical debate concerns whether brain reserve decreases over time as a function of chronological aging or accumulating pathology. While some researchers conceptualize brain reserve as the maximum attained volume during life (e.g., “static” [70]), others have referred to it as the status of the brain at any point in time (e.g., “dynamic” [61]). To illustrate the difference between these interpretations, we take the hypothetical example of an individual who develops late-onset AD. Before accumulation of AD pathology (i.e., amyloid plaques and neurofibrillary tangles), the brain has undergone other pathological changes (e.g., aggregation of other misfolding proteins and white matter lesions) and volume loss as a function of chronological aging. According to the first interpretation, this individual’s brain reserve is the volume of his brain prior to the onset of any age- or disease-related changes. Regardless of the volumetric decreases that occur after that point, his brain reserve (i.e., his maximum attained brain size) will remain the same. In contrast, the second conceptualization of brain reserve depends on which point of time is considered; it will be considerably lower at 80 years of age compared with a younger age, when there is a paucity of comorbid pathologies. See Fig. 2 for a schematic representation of both conceptualizations of brain reserve.

**Mechanisms behind brain reserve and effects on clinical progression**

There is very limited literature on the mechanisms underlying brain reserve and its specific effect on clinical progression. It has been suggested that greater brain reserve (e.g., higher synaptic density, neuronal count, or even a higher glia-to-neuron ratio) optimizes “the potential for functional adaptation to neurodegenerative processes” [53]. In this sense, the mechanism of brain reserve seems to be nothing more than “allowing more cognitive reserve”. Another, more generally used statement that is reminiscent of Mortimer and Satz’s theoretical models, is that higher brain reserve concerns “a higher (pathological) threshold before clinical symptoms of pathology become evident” (e.g., [64]). This description is rather abstract in the sense that the biological processes underlying this “threshold effect” are not specified. To allow advances in the field of brain reserve, it is essential to develop a mechanistic model explaining the link between greater brain volume and a higher threshold for clinical expression of pathology. The term “threshold” suggests that passive loss of brain structure without functional adjustment (which would reflect cognitive reserve) could occur in the absence of any cognitive effects, at least in the initial stages of AD (Fig. 3a, the “threshold model”). However, this implies that the affected structural properties (e.g., neurons, axons, synapses) were fully redundant and served no function in the healthy brain. With the exception of apoptosis (i.e., a coordinated death of cells that no longer contribute to healthy functioning, which is crucial for normal brain development [26]), this is unlikely from a biological perspective. A more likely scenario is that brain reserve is primarily associated with individual differences in premorbid levels of cognitive function, such that individuals with larger brains must undergo greater decrements in cognitive function before a level of objective

![Fig. 2](image-url)
clinical impairment is reached (Fig. 3b, the “initial advantage model”). In line with this hypothesis, current literature shows evidence of a direct relationship between brain size and general mental ability in cognitively normal adults [51].

Another possibility is that brain reserve is not (only) associated with higher premorbid cognitive function or a delayed cognitive decline, but rather a slower rate of clinical progression. According to Lövdén et al., the brain’s level of cognitive function is a result of the interplay between environmental demands and functional organismic supply [36]. This suggests that, although larger brains have the potential for a higher level of cognitive function, an individual’s actual premorbid level is determined by the cognitive complexity that is required for daily activities. Based on the premise that i) cognitive ability depends on environmental demands and ii) a healthy brain does not maintain functionally obsolete structural properties, a large brain would have more “computational units” available to achieve a given cognitive level than a smaller brain. Consequently, the workload placed on each individual neuron should be lower, resulting in a relatively small decrease in function with the loss of any particular structure (Fig. 3c, the “lower workload model”). Figure 3 depicts the various proposed mechanisms of brain reserve and their clinical effects (note that Fig. 3b and c are similar to the “further to fall” and “resistance to change” models from [53]). Future research should examine which model best captures the effects of a larger brain volume on clinical progression in the face of pathology.

**Operationalization of brain reserve**

While further debate on several theoretical aspects of brain reserve is thus needed, many practical attempts to find a suitable proxy for this concept have been made. The notion of brain reserve as a passive model that concerns the “hardware” (i.e., structural, anatomical; see glossary) rather than the “software” of the brain (i.e., functional processes; see glossary) has important implications for the operationalization of this concept. It has led to the assumption that brain reserve should be measured in a quantitative manner, for example by the number of neurons, synapses, and/or dendritic spines [10]. An attractive aspect of this hypothesis is that it does not attribute any specific neuronal feature or combination of features as the mediating substrate of reserve, and that it is differentiable from larger concepts of cognitive networks that might underlie cognitive reserve. Whatever the substrate of brain reserve may be, bigger brains allow for more of it, and more of it is better in the face of pathology, or so the hypothesis would state. This phenomenon would be represented as a net advantage rather than an overall advantage, as there are likely some (e.g., metabolic) costs to the maintenance of a larger brain [43]. Prior to the advent of brain imaging techniques, head circumference was often used as an in-vivo measure of brain size to quantify brain reserve. The rationale behind this is that the ultimate size of the cranial vault is determined by internal pressure from expanding brain parenchyma [62], and thus head circumference reflects the maximum attained brain size. There is evidence suggesting that head circumference indeed captures the influence of brain reserve on clinical outcomes. For example, a study including ~ 2000 older individuals showed that persons with probable AD and a circumference below 55 cm performed significantly worse on neuropsychological testing [21]. Another longitudinal study revealed that, among persons without dementia who carried the major risk allele for sporadic AD (apolipoprotein E ε4), head circumference was related to future development of AD dementia [8]. Nowadays, brain size can be more precisely estimated using T1-weighted structural magnetic resonance imaging (MRI) scans. This estimation can be performed manually or based on an automated
process that either i) determines the scaling factor or nonlinear transformation needed to register a native space image to an average template, or ii) calculates the total sum of probabilistic tissue class images (i.e., gray matter + white matter + cerebrospinal fluid volumes) [12, 39]. The intracranial volume (ICV) measure resulting from these techniques is currently the most accepted operationalization of brain reserve.

**A critical appraisal of intracranial volume as a brain reserve proxy**

ICV is an easily accessible measurement to summarize variation in premorbid brain size and is an attractive proxy for brain reserve because it represents an absolute limit on individual brain volumetric capacity. However, using ICV as a proxy for brain reserve comes with practical issues. First, ICV is not necessarily a straightforward measurement of total brain capacity as cortical surface area varies (in the form of folding) with some independence to brain size in humans [37, 63]. This implies that more subtle individual differences in brain reserve may not be captured by a volumetric measure such as ICV. It should also be stated that, while automated estimations of ICV show excellent reliability with human raters [39], variations in these automated approaches still tend to be systematically biased by other confounders, such as gender and total brain atrophy [45]. Another disadvantage of using ICV as a brain reserve proxy is that, in healthy individuals, brain volume varies systematically with ICV, leading to near uniform recommendation of ICV as a nuisance covariate in volumetric studies [6, 13, 25, 55]. Whether this confounding relationship is caused by the natural influence of brain volume on cortical shape [63], systematic error in linear registration [54], or a combination is unclear. Regardless, the question must be raised whether a measurement can be both a proxy for brain reserve and a common nuisance covariate, and how this might play out in the context of neuroimaging studies. Little work has been done to examine or disentangle the methodological versus biological influence of ICV on morphometry, or how either may somehow relate to cognitive outcomes. In effect, covarying a morphometric analysis for ICV is both adjusting for the effects of linear transformation to a common space (a necessary step), but also incorporating information about premorbid brain state into the model. This somewhat convoluted concept remains a limitation of using ICV as a proxy for brain reserve, particularly in volumetric studies of aging and AD. Its confounding relationship with brain morphometry creates difficulties in planning a clean design of neuroimaging studies of the brain (and cognitive) reserve (e.g., [68]). Finally, the more dynamically we define brain reserve on a conceptual level (see previous section on unclarified theoretical issues), the more indirect becomes its relationship with ICV. As ICV is a fixed measure that reflects maximum attained brain volume, it does not change as a function of chronological aging or emergence of a neurodegenerative disease [24]. As a consequence, both positive and negative changes in brain reserve (e.g., due to lifestyle, or aging and pathology) cannot be captured with this proxy.

**Meta-analysis of the effect of intracranial volume on cognition in Alzheimer’s disease**

So far, our narrative review of the literature suggests a possible beneficial effect of ICV as a proxy for brain reserve on cognitive function. Results, however, have been mixed across studies, with some studies indicating a positive effect [22] while others report no effect [58] or even a negative effect [15]. We set out to systematically review the available literature quantifying the effects of ICV on cognitive function, and aggregate all results into a meta-analysis. Since the primary focus of this viewpoint is on aging and AD, only studies including these populations were included in the meta-analysis. Please note that, although we raise several critical points on a theoretical level regarding the use of ICV as a brain reserve proxy, we nevertheless aim to examine its empirical usefulness because it is currently the most accepted and widely used measure of brain reserve.

**Methods**

We searched the PubMed/MEDLINE database for eligible studies published until 8 November 2017. The following combination of search terms were applied: “(Intra(-)cranial volume(s)/capacity/size/space”, “(pre-)morbid brain size/volume”, “dementia”, “AD”, “mild cognitive impairment/MCI”, “elderly”, “ageing” and “(cognitive/brain/neural) reserve”. Additionally, reference lists of papers were cross-checked. Only peer-reviewed articles (written in or translated to English) were considered eligible. Studies were required to include a continuous or categorical (e.g., small versus large volume) measure of ICV as measured by MRI. ICV could be assessed either as a main predictor or a covariate (if an effect size was reported). Furthermore, samples could include the cognitively normal elderly, or patients with mild cognitive impairment (MCI) or dementia [3, 40]. Studies exclusively including patients with neurodegenerative diseases other than AD were excluded. Samples including patients with mixed or unknown dementia diagnoses were included (since AD is the most likely a priori diagnosis), as well as samples combining AD patients with a small proportion of patients with an alternative diagnosis. Predicted measures should contain a clinical outcome, either continuous (e.g., Mini-Mental State Examination (MMSE) or episodic memory scores) or categorical (e.g., cognitively impaired (yes/no) or longitudinal conversion to cognitive
Importantly, since brain reserve serves to explain discrepancies between observed and expected symptom severity based on the severity of underlying pathology [30], studies were required to include an operationalization of neuropathology (e.g., atrophy; see glossary). In order to examine the effects of ICV on cognition at a given level of pathology, studies should have included this operationalization of neuropathology in the same model as ICV. OpenMetaAnalyst software was implemented to determine the overall effects of ICV on quantified measures of cognition. Due to expected heterogeneity (e.g., sample composition and nuisance variables), effects sizes were assumed to be similar but not equal across studies. Therefore, a random-effects meta-analysis was performed [9]. Significance for random effects of ICV was set at $p < 0.05$.

**Results**

**Study description**

Database queries yielded a total of 583 results, of which 10 were eligible to be included (Fig. 4) [15, 18, 22, 41, 44, 50, 56, 58, 69, 70].

These 10 studies included a total of 2675 patients. Two studies [69, 70] likely included a partly overlapping sample of subjects since these study samples were taken from the same cohort. Two studies included (sub)samples of only AD dementia patients [22, 41] and one included only healthy elderly [50]; all other samples were mixed (e.g., healthy elderly, MCI, and/or dementia subjects) or community samples with unknown diagnoses. The mean age of all subjects was $69.8 \pm 5.8$ years, 48% were male, and mean education was $11.8 \pm 1.3$ years. All studies calculated ICV by summation of gray matter, white matter, and cerebrospinal fluid volumes, except for [41] which defined premorbid brain volume by regressing ICV on whole brain volume, while correcting for age and sex. To obtain the premorbid brain volume, the regression coefficient was multiplied by the ICV and the constant was added. Across studies, different nuisance variables were taken into account, but most models included age and sex (Table 1). Furthermore, operationalization of neuropathology included in the models also varied across studies but could be roughly divided into measures of hippocampal volume, white matter, gray matter, and total brain volume (Table 1).

**Effects of intracranial volume on cognition**

Of the 10 selected studies, six provided a continuous measure of cognition and were therefore suitable to be included in a meta-analysis. Five of these studies had a cross-sectional design and one had a longitudinal design (Table 1). This subsample consisted of 2262 subjects, of which 48.5% were male, the mean age was $69.8 \pm 4.9$ years, and mean education was $11.7 \pm 1.2$ years. Across these six studies, 26 cognitive tests were performed which could be categorized into the following domains: global cognition, memory, attention and/or executive functions, visuo-spatial ability, language, and IQ. An
| Study                  | n    | Subjects                        | Age     | Male (%) | Education (years) | Design                      | Nuisance                      | Corrected for                  | Outcome                          | Effect |
|------------------------|------|---------------------------------|---------|----------|-------------------|-----------------------------|-------------------------------|--------------------------------|----------------------------------|--------|
| Mori, 1997*            | 41   | Mild to moderate AD             | 70.2(7.1)| 38.3     | 8.9 (2.3)         | Cross-sectional             | Age, sex, education           | Atrophy                        | ADAS-Cog<sup>a</sup>              | −0.12  |
| Staff, 2004            | 58   | Unknown                         | 79      | 57.6     | 9.8 (1.6)         | Cross-sectional             | Childhood IQ, sex             | WMH                            | WAIS-R Full IQ<sup>a</sup>        | 0.40   |
| Christensen, 2009 [15] | 416  | Unknown                         | 62.6(1.4)| 52       | 14 (2.6)          | Longitudinal, 4-year change| Age, sex, education           | Atrophy and WMH               | CVLT: Immediate<sup>b</sup>      | −0.39  |
| Farias, 2012           | 401  | Mixed HC, MCI and dementia      | 75(6.9) | 37.3     | 12.3 (4.8)        | Cross-sectional             | Sex, height                   | TBV, hippocampal volume, and WMH| SENAS: Semantic memory<sup>b</sup> | 0.20   |
| Royle, 2013            | 327  | HC                              | 72.5(0.7)| 100      | −                | Cross-sectional             | Age                           | TBV                            | Episodic memory<sup>b</sup>      | 0.08   |
|                        | 297  |                                 | 72.6(0.73)| 0        | −                |                              | GM and WM                     |                                | Executive function<sup>c</sup>  | 0.27   |
|                        |      |                                 |         |          |                   |                              | TBV                           |                                | Spatial ability<sup>d</sup>      | 0.16   |
| Groot, 2018            | 201  | Aβ+ preclinical and prodromal AD| 666(7.5)| 53       | 10–11**           | Cross-sectional             | Age, sex, education, scanner | Atrophy                        | Memory<sup>b</sup>               | 0.12   |
|                        |      | Aβ+ probable AD                 | 462(7.4)| 47       | 10–11**           |                              |                               |                                | Attention<sup>f</sup>            | 0.06   |
|                        |      |                                 |         |          |                   |                              |                               |                                | Executive<sup>c</sup>            | 0.18   |
|                        |      |                                 |         |          |                   |                              |                               |                                | Language<sup>f</sup>             | −0.03  |
|                        |      |                                 |         |          |                   |                              |                               |                                | Visuospatial<sup>d</sup>         | 0.14   |
|                        |      |                                 |         |          |                   |                              |                               |                                | MMSE<sup>a</sup>                | 0.16   |
|                        |      |                                 |         |          |                   |                              |                               |                                | Memory<sup>b</sup>               | 0.10   |
|                        |      |                                 |         |          |                   |                              |                               |                                | Attention<sup>f</sup>            | 0.14   |
|                        |      |                                 |         |          |                   |                              |                               |                                | Executive<sup>c</sup>            | 0.15   |
|                        |      |                                 |         |          |                   |                              |                               |                                | Language<sup>f</sup>             | 0.05   |
|                        |      |                                 |         |          |                   |                              |                               |                                | Visuospatial<sup>d</sup>         | 0.13   |
| Study | n | Subjects | Age | Male (%) | Education (years) | Design | Nuisance | Corrected for | Outcome | Effect |
|-------|---|----------|-----|----------|-------------------|--------|----------|--------------|---------|--------|
| Wolf, 2004 [69] | 73 | HC, MCI | 79.1 | 49.3 | 11.3 | Cross-sectional | Education | Left hippocampus | Predicting HC vs MCI (OR) | 1.04*** |
| | 70 | MCI, dementia | 78.7 | 34.3 | 10.8 | Cross-sectional | Age | RBV | Predicting MCI vs dementia (OR) | 1.05*** |
| Wolf, 2004 [70] | 167 | HC, MCI, AD, VaD | 60.7 (9.9) | 43 | – | Cross-sectional | Age, sex | Hippocampal atrophy (visual assessment) | HC vs cognitive impairment (OR compared with smallest quartile) | 2.9 |
| Silbert, 2009 [56] | 49 | HC (at baseline) | 84.1 (6.2) | 47 | 14.5 (2.7) | Longitudinal, 10-year change | Age, MMSE, APOEε4 status | ΔWMH, ΔvCSF, and hippocampal, vCSF and WMH | Persistent cognitive decline (HR) | 10 |
| Negash, 2013 [44] | 54 | Aβ+ HC and AD | 72.7 | 42.6 | 14.4 | Cross-sectional | Age, sex, education, APOEε4 status | MTL volume | Resilience (normal despite Aβ+; OR) | 1.01 |

Bold effects are reported to be significant according to study-specific statistical thresholds.

Aβ, amyloid-beta; AD, Alzheimer’s disease; ADAS-Cog, Amsterdam dementia assessment scale—cognitive subscale; APOEε4, apolipoprotein ε4; AVLT, auditory verbal learning test; CVLT, California verbal learning test; GM, gray matter; HC, healthy controls; HR, hazard ratio; ICV, intracranial volume; IQ, intelligence quotient; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; MTL, medial temporal lobe; OR, odds ratio; RBV, relative brain volume (brain volume to ICV ratio); RPM, Raven’s progressive matrices; SDMT, symbol-digit modalities test; SENAS, Spanish-English neuropsychological assessment scale; TBV, total brain volume; VaD, vascular dementia; vCSF, ventricular cerebrospinal fluid; WAS-IV, Wechsler adult intelligence scale-revised; WM, white matter; WMH, white matter hyperintensity.

*Premorbid brain volume calculated as regression coefficient of (age + sex + ICV = whole brain volume) multiplied by ICV + constant.

**Categorization according to the Verhage scale [65] converted into years.

***Odds ratios calculated from β coefficients using $e^{\beta}$.

†This effect was considered an outlier and was not included in the meta-analysis.

Global cognition
Memory
Attention/executive functions
Visuospatial ability
Intelligence
Language
overview of each test used and the categorization into domains is provided in Table 1. One study [15] reported an effect of $-1.45$ of ICV on the California verbal learning test, delayed recall condition, which was a statistical outlier and therefore excluded from the analyses. The main analysis for the quantitative assessments of cognition, including all cognitive domains, revealed a positive random effect of ICV on cognition ($0.10$, $95\%$ confidence interval (CI) $0.05$–$0.16$; $p < 0.001$; Fig. 5). This indicates that, across all studies, ICV has a positive effect on cognitive functioning when controlling for neuropathology.

Four studies provided categorical cognitive outcomes. A longitudinal assessment [56] reported a hazard ratio of $1.0$ for ICV on conversion to persistent cognitive decline, indicating that ICV does not affect the risk of conversion. Another study [69] reported that ICV predicts being cognitively normal versus MCI (odds ratio $1.4$) and having MCI versus dementia (odds ratio $1.5$), while a similar assessment [70] showed that having an ICV in the lowest quartile confers an odds ratio of $2.9$ of being cognitively impaired. Furthermore, another study [44] showed that ICV is a significant covariate (odds ratio $1.01$) associated with resilience, defined as being cognitively intact despite positive biomarkers for amyloid-$\beta$. Taken together, these results show that, while odds ratio were generally close to $1$ (except in [70]), ICV is a significant predictor for cross-sectional cognitive state.

**Methodological considerations**

In this meta-analysis, studies that assessed the effects of ICV on cognition but did not include a measure of neuropathology were not included. The three largest studies that assessed the effects of ICV in this manner found no associations with cognition or dementia risk [17, 29, 62]. However, brain reserve serves to explain discrepancies between observed and expected symptom severity based on the severity of the underlying pathology [30] and we argue that studies that do not correct for the degree of neuropathology do not measure brain reserve. Based on the absence of an effect when not correcting for neuropathology and the presence of an effect when models are corrected for neuropathology, we hypothesize that direct effects of ICV on cognition are not detectable but the “buffer” effect of ICV between pathology and symptoms (which constitutes brain reserve) is detectable.

We would have ideally conducted additional meta-analyses in subsamples of studies that included patients in the same cognitive state (e.g., healthy controls versus MCI versus dementia) and studies using similar

---

*[Fig. 5](#) Forest plot of main analysis on quantitative cognitive outcomes. a Results according to the cognitive state of the samples; b results according to the measure of corrected neuropathology. Data points indicate a reported effect. Standard errors are not displayed as these were rarely reported. Total effect was calculated using random-effects meta-analysis including all effects across cognitive outcomes and populations. CI confidence interval, IQ intelligence quotient*
measures of neuropathology. However, due to the paucity of studies that fit the inclusion criteria (n = 6 for quantitative assessment) this would have resulted in very few studies per analysis. The effects in healthy controls would, for instance, be based on only one study [50] and the differences in effects between healthy subjects and other cognitive states would thus not be distinguishable from study effects. Visual inspection of the effects (color-coded by cognitive state in Fig. 5a) indicates that there are no clearly identifiable differences in effects of brain reserve, but this observation needs to be interpreted with caution. Furthermore, visual inspection of the effects when color-coded according to the corrected marker of neuropathology (Fig. 5b) suggests that there is no effect of ICV when correcting for white matter hyperintensity (WMH) alone. However, this observation is based on results in two samples from a single study [58] and may thus represent a study effect. Finally, we were unable to account for the influence of the different covariate sets used across studies. The most important covariates, age and sex, were included in most—but not all—studies, and adjustment for education, scanner, and APOEε4 status varied across studies. One study also corrected for childhood IQ [58], which may have led to an attenuation of the observed effect in this study due to the association between childhood IQ and ICV [67]. Similarly, one study corrected for height [18]. However, although height and ICV are clearly related [38] and associations between height and cognition have also been found [2] it is possible that correcting for height results in removal or attenuation of true effects of ICV (i.e., brain reserve).

Conclusion
To summarize, the concept of brain reserve has been around since 1940 and its use in the scientific literature has increased ever since. While consensus on some theoretical aspects of its definition and underlying mechanisms has not yet been reached, the field has made significant progress in the operationalization of brain reserve. ICV, currently the most accepted proxy, is an easily accessible measure obtained from structural MRI. However, it has a limited utility in detailing the biological substrate of brain reserve, and a confounding relationship with brain morphology that complicates the measurement of brain reserve in volumetric studies. Nonetheless, a meta-analysis of 10 studies showed that ICV generally has a positive relationship with cognitive performance after adjusting for pathology, indicating that this measure does capture some aspect of brain reserve. Although the use of ICV as a proxy for this concept is thus currently warranted, we emphasize the need for further development of more optimal measures of brain reserve. For example, the utility of dynamic measures as proxies of brain reserve (e.g., whole-brain or hippocampal volumes instead of ICV) could be explored, for example using a meta-analysis including studies focusing on associations between absolute volumetric measures (not adjusted for ICV) and cognition. Also, possible candidates in future studies would include diffusion tensor imaging or indices of microstructural integrity of the brain, such as in-vivo examination of dendritic spine length, synaptic density, or synaptic proteins using synaptic vesicle tracers for positron emission tomography (PET) [10, 19]. Another possible avenue for future research is the assessment of the associations between genetic factors and brain reserve. It has already been shown that there is an overlap in the genetic variations associated with cognition and ICV [2, 46]. Another interesting target is the methionine (Met) substitution for valine (Val) at codon 66 (Val66Met), a single-nucleotide polymorphism in the brain-derived neurotrophic factor (BDNF) gene that has been associated with alterations in brain anatomy [14]. Now, with the introduction of the Allen human brain atlas [23], one may explore the interplay between more dynamic measures of brain reserve and the relative gene expression across the entire human brain. These new developments allow exploration of gene expression pathways that contribute to, or mediate the effects of, brain reserve. Ultimately, this could enable an operationalization of brain reserve based on genetic information. Finally, in order to further improve the measurement of brain reserve, a more clearly defined theoretical framework of this concept is essential.

Abbreviations
AD: Alzheimer’s disease; ICV: Intracranial volume; MCI: Mild cognitive impairment; MRI: Magnetic resonance imaging

Funding
Research of the VUMC Alzheimer Center is part of the Neurodegeneration research program of the Neuroscience Campus Amsterdam. The VUMC Alzheimer Center is supported by Alzheimer Nederland and Stichting VUMC funds. This research was funded by the Internationale Stichting Alzheimer Onderzoek (ISAO) (to RO).

Availability of data and materials
The meta-analysis was performed in OpenMetaAnalyst software, which is freely available from http://www.cebm.brown.edu/openmeta/. The data used for the meta-analysis comprised of the effect sizes, which are featured in the “effect” column of Table 1 and are therefore available in this article. The dataset is available in an OpenMetaAnalyst recognized file format upon request. Any additional information regarding studies included in the meta-analysis can be obtained from the respective papers listed in the reference list.

Authors’ contributions
ACvL wrote the sections that discuss the historical background, unclarified theoretical issues, and the operationalization of brain reserve, and was involved in several discussions with JWV and RO that resulted in the theoretical foundation of this manuscript, and carefully reviewed the sections of the manuscript. CG carried out the meta-analysis and carefully reviewed the other sections of the manuscript. JWV wrote the critical appraisal of ICV as a proxy for brain reserve, was involved in several discussions with ACvL and RO that resulted in the theoretical foundation of this manuscript, and carefully reviewed all sections of the manuscript. WWMvDf carefully revised the manuscript. RO, the senior author in this project, was involved in (and chaired) several discussions with ACvL and JWV that resulted in the theoretical foundation of this manuscript,
worked with AChE in shaping the general framework, and carefully revised all sections of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Glossary
Brain volume
The total volume of the brain when all structural properties (i.e., gray matter and white matter) are considered.

Intracranial volume
The total volume of the interior of the cranium (i.e., skull), thus containing both brain volume and cerebrospinal fluid.

Atrophy
Loss of brain structure (e.g., neurons, glial cells).

Passive
A change in brain to which no direct adaptation or response occurs, or a latent phenomenon or quality that covertly existed but now becomes visible when its surroundings are changing.

Active
A change in the brain to which a direct adaptation or response occurs, or a phenomenon or quality that was born out of necessity to cope with brain changes (antonym of “passive”).

Hardware
The (infra)structure of the brain, which can be measured with structural neuroimaging (in vivo) or at neuropathological examination (ex vivo).

Software
The manner in which the (infrastructure) of the brain is used, which can only be measured with functional neuroimaging during life.

Static
A concept or measure that is fixed; it cannot change over time and thus an individual will always have the same value or score.

Dynamic
A concept or measure that can change over time, such that its values or scores can fluctuate (i.e., increase and decrease) within individuals.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1 Department of Neurology and Alzheimer Center, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
2 Department of Radiology and Nuclear Medicine, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
3 Department of Radiology and Nuclear Medicine, Neuroscience Campus Montreal, McGill University, Montreal, QC, Canada.
4 Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
5 Department of Clinical Memory Research, Lund University, Lund, Sweden.

Published online: 11 September 2018

References
1. [No authors listed]. Reserve capacity of the brain. Br Med J. 1940;2(4167):673–4.
2. Abbott RO, White LR, Ross GW, Petrovitch H, Masaki KH, Snowdon DA, Curb JD. Height as a marker of childhood development and late-life cognitive function: the Honolulu-Asia aging study. Pediatrics. 1998;102(3):602–9.
3. Albert MS, Delkowsky D, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;3:270–9.
4. Arenaza-Urquijo EM, Wirth M, Chetelat G. Cognitive reserve and lifestyle: moving towards preclinical Alzheimer’s disease. Front Aging Neurosci. 2015;7:134.
5. Bartley AJ, Jones DW, Weinberger DR. Genetic variability of human brain size and cortical gyral patterns. Brain. 1997;120:257–69.
6. Barnes J, Ridgway GR, Bartlett J, Henley SM, Lehmann M, Hobbs N, Clarkson MJ, MacManus DG, Ourselin S, Fox NC. Head size, age and gender adjustment in MRI studies: a necessary nuisance? NeuroImage. 2010;53(4):1244–55.
7. Baldini M, Fulmore CA, Tarnt AN, Simeon LR, Pavlova L, Paposka V, et al. Human hippocampal neurogenesis persists throughout aging. Cell Stem Cell. 2018;22(4):589–99.
8. Borenstein Graves A, Mortimer JA, Bowen JD, McCormick WC, McCurry SM, Schellenberg GD, Larson EB. Head circumference and incident Alzheimer’s disease: modification by apolipoprotein E. Neurology. 2001;57(8):1453–60.
9. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Research Synthesis Methods. 2010;1(2):97–111.
10. Boros BD, Greathouse KM, Gentry EC, Curtis KA, Birchall EL, Gearing M, Herskowitz JH. Dendritic spines provide cognitive resilience against Alzheimer’s disease. Ann Neurol. 2017;82(4):602–14.
11. Braak H, Del Tredici K. The preclinical phase of the pathological process underlying sporadic Alzheimer’s disease. Brain. 2015;138(10):2814–33.
12. Buckner RL, Head D, Parker J, Fotenos AF, Marcus D, Morris JC, Snyder AZ. A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. Neuroimage. 2004;23(2):724–38.
13. Crowley S, Huang H, Tanner J, et al. Erratum to: considering total intracranial volume and other nuisance variables in brain voxel based morphometry in idiopathic PD. Brain Imaging and Behavior. 2017; https://doi.org/10.1007/s11682-017-9709-8.
14. Chen ZY, Jing D, Bath KG, Issac A, Khan T, et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science. 2006;314(5796):140–3.
15. Christensen H, Battenhøj PJ, Mackinnon AJ, Anstey KJ, Wen W, Sachdev PS. Education, atrophy, and cognitive change in an epidemiological sample in early old age. Am J Geriatr Psychiatry. 2009;17(3):218–26.
16. Eriksson PS, Perfilieva E, Björk-Eriksson T, Alborn AM, Nordborg C, Peterson DA, Gage F. Neurogenesis in the adult human hippocampus. Nat Med. 1998;4:1313–7.
17. Edland SD, Xu Y, Plevak M, O’Brien P, Tangalos EG, Petersen RC, Jack CR Jr. Total intracranial volume: normative values and lack of association with Alzheimer’s disease. Neurology. 2002 Jul 23;59(2):272–4.
18. Farias ST, Mungas D, Reed B, Carmichael O, Beckett L, Harvey D, Olchney J, Simmonds A, Decarli C. Maximal brain size remains an important predictor of cognition in old age, independent of current brain pathology. Neurobiol Aging. 2012;33(8):1758–68.
19. Finnema SJ, Nabulsi NB, Eid T, Detyniecki K, Lin SF, Chen MK, Dhaher R, van Loenhoud et al. Alzheimer’s Research & Therapy (2018) 10:91
20. Finlayson M, Hedges LV, Higgins JPT, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Research Synthesis Methods. 2010;1(2):97–111.
21. Graves AB, Mortimer JA, Larson EB, Wendos A, Bowen JD, McCormick WC. Head circumference as a measure of cognitive reserve. Association with severity of impairment in Alzheimer’s disease. Br J Psychiatry. 1996;168:186–92.
22. Groot C, van Loenhoud AC, Barkhof F, van Berkel BMN, Koene T, Teunissen CC, Scheltens P, van der Flier WM, Ossenkoppele R. Differential effects of cognitive and brain reserve on cognition in AD. Neurobiology of Aging. 2018;90(2):149–56.
23. Hawrylcz MJ, Lein ES, Guillozet-Bongaarts AL, et al. An anatomically comprehensive atlas of the adult human brain transcriptome. Nature. 2012;489(7416):391–9.
24. Hasan KM, Wallmuni IS, Kraemer LA, Frye RE. Human brain atlas-based volumetry and relaxometry: application to healthy development and natural aging. Magn Reson Med. 2010;64:1382–9.
25. Henley SM, Ridgway GR, Scalfill R, Klöppel S, Tabrizi SJ, Fox NC, Kassubek J, EHDN Imaging Working Group. Pitfalls in the use of voxel-based...
morphometry as a biomarker: examples from Huntington disease. Am J Neuroradiol. 2010;31(4):711–9.

26. Hutchins B, Barger SW. Why neurons die: cell death in the nervous system. Anat Rec. 1998;253(3):79–90.

27. Jack CR Jr, Wiske HJ, et al. Age-specific population frequencies of cerebral beta-amyloidosis and neurodegeneration among people with normal cognitive function aged 50–89 years: a cross-sectional study. Lancet Neurool. 2014;13(10):997–1005.

28. Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, Visser PJ. The amyloid biomarker study group. Prevalence of cerebral amyloid pathology in persons without dementia a meta-analysis. J Am Med Assoc. 2015;313(19):1928–38.

29. Jenkins R, Fox NC, Rossor AM, Harvey RJ, Rossor MN. Intracranial volume and Alzheimer disease: evidence against the cerebral reserve hypothesis. Arch Neurool. 2000;57:220–4.

30. Jones RN, Manly J, Glymour MM, Rentz DM, Jefferson AL, Stern Y. Conceptual and measurement challenges in research on cognitive reserve. J Int Neuropsychol Soc. 2011;17:593–601.

31. Katzman R, Terry R, DeTeresa R, Brown T, Davies P, Fuld P, Renbign X, Peck A. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol. 1988;23(2):138–44.

32. Kempermann G, Gage FH, Aigner L, Song H, Curtis MA, Thurer S, et al. Human adult neurogenesis: evidence and remaining questions. Cell Stem Cell. 2018;5(1):394–403.

33. Kuipers SD, Bramham CR, Cameron HA, Fitzsimons CP, Korosi A, Lucassen PJ. Gamma-aminobutyric acid receptor subunit 1 mRNA: an immunohistochemical tool for the detection of adult hippocampal neurogenesis. J Chem Neuroanat. 2004;27(4):361–8.

34. Lusted E, Nair K, Thompson PM, Rex DE, Jancke L, Price BJ. Brain growth. Cen Afr J Med. 1997;43:264–9.

35. Lynn R. A nutrition theory of the secular increases in intelligence; positive correlation between height, head size and IQ. Br J Educ Psychol. 1980;50:298–307.

36. Malone IB, Leung KK, Clegg S, Barnes J, Whitwell JL, Ashburner J, Fox NC, Rentz DM, Jefferson AL, Stern Y. Intracranial volume and Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association Work Group on Diagnostic Guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9.

37. McPherson KS, Papadimitriou C, Pfefferbaum A. The association of clinical and neurological findings and its bearing on the classification and aetiology of Alzheimer’s disease. Br Med Bull. 1986;42:42–50.

38. Royle NA, Booth T, Valdés Hernández MC, Penke L, Murray C, Gow AJ, Maniega SM, Starr J, Bastin ME, Deary IJ, Wardlaw JM. Estimated maximal and current brain volume predict cognitive ability in old age. Neurobiol Aging. 2013;34(12):2726–33.

39. Ruzhton JP, Ankney CD. Whole brain size and general mental ability: a review. Int J Neurosci. 2009;119(S1):692–732.

40. Satz P. Brain reserve capacity on symptom onset after brain injury: a formulation and review of evidence for threshold theory. Neuropsychology. 1993;7:273–95.

41. Schofield P. Alzheimer’s disease and brain reserve. Australasian Journal on Ageing. 1999;18:10–4.

42. Schwab NA, Tanner JJ, Nguyen PT, Schmalfuss IN, Bowers D, Okun M, Price CC. Proof of principle: transformation approach alters caudate nucleus volume and structure-function associations. Brain Imaging and Behavior. 2015;9:744.

43. Schwieze CG, Gunter JL, Wiste HJ, Pobjeckyi SA, Weigand SD, Ward CP, et al. A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer’s disease severity. NeuroImage: Clinical. 2016;11:802–12.

44. Silbert LC, Howieson DB, Dodge H, Kaye JA. Cognitive impairment risk: white matter hyperintensity progression matters. Neurology. 2009;73(2):120–5.

45. Sorells SF, Paredes MF, Cebrian-Silla A, Sandoval K, Qi D, Kelley KW, et al. Human hippocampal neurogenesis drops sharply in children to undetectable levels in adults. Nature. 2018;555(7696):377–81.

46. Staff RT, Murray AD, Deary IJ, Whalley LJ. What provides cerebral reserve? Brain. 2004;127(5):1191–9.

47. Spaulding KL, Bergmann O, Alkass K, Bernard S, Salehpour M, Huttner HB, Bostrom E, Westerlund I, Vial C, Buchholz BA, Possnert G, Mesh DC, Druhd H, Friul J. Dynamics of hippocampal neurogenesis in adult humans. Cell. 2013;153(6):1219–27.

48. Stern Y. Cognitive reserve in ageing and Alzheimer’s disease. Lancet Neurool. 2012;11(11):1006–12.

49. Stern Y. An approach to studying the neural correlates of reserve. Brain Imaging and Behavior. 2017;11:410–6.

50. Tate DF, Neely ES, Norton MC, Tischanz JT, Miller MJ, Wolfson L, Hullette C, Leslie C, Welsh-Bohmer KA, Plasman B, Bigler ED. Intracranial volume and dementia: some evidence in support of the cerebral reserve hypothesis. Brain Res. 2011;1385:151–62.

51. Rushton JP, Ankney CD. Whole brain size and general mental ability: a review. Int J Neurosci. 2009;119(S1):692–732.

52. Satz P. Brain reserve capacity on symptom onset after brain injury: a formulation and review of evidence for threshold theory. Neuropsychology. 1993;7:273–95.

53. Schofield P. Alzheimer’s disease and brain reserve. Australasian Journal on Ageing. 1999;18:10–4.

54. Schwab NA, Tanner JJ, Nguyen PT, Schmalfuss IN, Bowers D, Okun M, Price CC. Proof of principle: transformation approach alters caudate nucleus volume and structure-function associations. Brain Imaging and Behavior. 2015;9:744.

55. Schwieze CG, Gunter JL, Wiste HJ, Pobjeckyi SA, Weigand SD, Ward CP, et al. A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer’s disease severity. NeuroImage: Clinical. 2016;11:802–12.

56. Silbert LC, Howieson DB, Dodge H, Kaye JA. Cognitive impairment risk: white matter hyperintensity progression matters. Neurology. 2009;73(2):120–5.

57. Sorells SF, Paredes MF, Cebrian-Silla A, Sandoval K, Qi D, Kelley KW, et al. Human hippocampal neurogenesis drops sharply in children to undetectable levels in adults. Nature. 2018;555(7696):377–81.

58. Staff RT, Murray AD, Deary IJ, Whalley LJ. What provides cerebral reserve? Brain. 2004;127(5):1191–9.

59. Spaulding KL, Bergmann O, Alkass K, Bernard S, Salehpour M, Huttner HB, Bostrom E, Westerlund I, Vial C, Buchholz BA, Possnert G, Mesh DC, Druhd H, Friul J. Dynamics of hippocampal neurogenesis in adult humans. Cell. 2013;153(6):1219–27.

60. Stern Y. Cognitive reserve in ageing and Alzheimer’s disease. Lancet Neurool. 2012;11(11):1006–12.

61. Stern Y. An approach to studying the neural correlates of reserve. Brain Imaging and Behavior. 2017;11:410–6.

62. Tate DF, Neely ES, Norton MC, Tischanz JT, Miller MJ, Wolfson L, Hullette C, Leslie C, Welsh-Bohmer KA, Plasman B, Bigler ED. Intracranial volume and dementia: some evidence in support of the cerebral reserve hypothesis. Brain Res. 2011;1385:151–62.

63. Toro R, Perron M, Pike B, Richer L, Veillette S, Pausova Z, Paus T. Brain size and folding of the human cerebral cortex. Cereb Cortex. 2008;18(10):2352–7.

64. Tucker AM, Stern Y. Cognitive reserve in ageing. Curr Alzheimer Res. 2011;8(6):354–60.

65. Verhaeghe F. Intelligente en leeftijd: Onderzoek bij Nederlanders van twaalf tot zevenenveertig jaar. [Intelligence and age: Research study in Dutch individuals age twelve to seventy-seven]. Assen: Van Gorcum/Prakke & Prakke. 1964.

66. Valero J, Paris I, Sierra A. Lifestyle shapes the dialogue between environment, microglia, and adult neurogenesis. ACS Chem Neurosci. 2016;7(4):442–53.

67. van Leeuwen M, Peper JS, van den Berg SM, Brouwer RM, Hulshof Pol HE, Kahn R, Boomma DI. A genetic analysis of brain volumes and IQ in children. Intelligence. 2009;37(2):181–91.

68. van Loenhoud et al. Alzheimer’s Research & Therapy (2018) 10:91

69. Wolf H, Hensel A, Kruggel F, Riedel-Heller SG, Arendt T, Wahlund LO, Gertz HJ, Structural correlates of mild cognitive impairment. Neurobiol Aging. 2004a;25(7):913–24.

70. Wolf H, Hensel A, Kruggel F, Redel-Heller SG, Arendt T, Wahlund LO, Gertz HJ. Structural correlates of mild cognitive impairment. Neurobiol Aging. 2004a;25(7):913–24.

71. Wolf H, Julin P, Gertz HJ, Winblad B, Wahlund LO. IQ in mild cognitive impairment, AD and vascular dementia: evidence for brain reserve? Int J Geriatr Psychiatry. 2004b;19(10):995–1007.